## ICMJE DISCLOSURE FORM

Date:5/6/2021
Your Name:Umang Swami, MD, MS
Manuscript Title: Cancer Immunotherapy: Recent Advances and Challenges
Manuscript number (if known): ATM-2020-CI-10(ATM-21-2325)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_XNone	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastXNone	36 months
3	Royalties or licenses	XNone	
4	Consulting fees	None	Seattle Genetics

	_XNone	
lectures, presentations,		
speakers bureaus,		
manuscript writing or		
educational events		
Payment for expert	X None	
•		
,		
Support for attending	X None	
meetings and, or traver		
	_XNone	
pending		
Participation on a Data	_XNone	
Safety Monitoring Board or		
Advisory Board		
Leadership or fiduciary role	XYes	
in other board, society,		
committee or advocacy		
group, paid or unpaid		
Stock or stock options	_XNone	
Receipt of equipment,	X None	
materials, drugs, medical		
materials, drugs, medical writing, gifts or other	X None	
materials, drugs, medical writing, gifts or other services	XNone	
materials, drugs, medical writing, gifts or other services Other financial or non-	XNone	
materials, drugs, medical writing, gifts or other services Other financial or non-	XNone	
materials, drugs, medical writing, gifts or other services Other financial or non-	XNone	
materials, drugs, medical writing, gifts or other services Other financial or non-financial interests		owing hox:
materials, drugs, medical writing, gifts or other services Other financial or non-		owing box:
materials, drugs, medical writing, gifts or other services Other financial or non-financial interests  se summarize the above contact the services	nflict of interest in the fol	-
materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	nflict of interest in the fol	-
materials, drugs, medical writing, gifts or other services Other financial or non-financial interests  se summarize the above contact the services	nflict of interest in the fol	-
materials, drugs, medical writing, gifts or other services Other financial or non-financial interests  se summarize the above contact the services	nflict of interest in the fol	-
materials, drugs, medical writing, gifts or other services Other financial or non-financial interests  se summarize the above contact the services	nflict of interest in the fol	-
materials, drugs, medical writing, gifts or other services Other financial or non-financial interests  se summarize the above contact the services	nflict of interest in the fol	-
materials, drugs, medical writing, gifts or other services Other financial or non-financial interests  se summarize the above contact the services	nflict of interest in the fol	-
materials, drugs, medical writing, gifts or other services Other financial or non-financial interests  se summarize the above contact the services	nflict of interest in the fol	-
materials, drugs, medical writing, gifts or other services Other financial or non-financial interests  se summarize the above contact the services	nflict of interest in the fol	-
	educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

## ICMJE DISCLOSURE FORM

Date:5/6/2021
Your Name:Mohammed Milhem, MD
Manuscript Title: Cancer Immunotherapy: Recent Advances and Challenges
Manuscript number (if known): ATM-2020-CI-10(ATM-21-2325)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	None	Blueprints Medicine, Immunocore, Amgen, Trieza, Array Biopharma, Biontech and Novartis

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_XNone	
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel		
	meetings and/or traver		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	Yes	Exicure Executive Steering Committee
	in other board, society,		_
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
			<u> </u>

## Please summarize the above conflict of interest in the following box:

Dr. Milhem reports consultancy/advisory board for Blueprints Medicine, Immunocore,
Amgen, Trieza, Array Biopharma, Biontech and Novartis. He also currently serves on Exicure
Executive Steering Committee.

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.